Enhancing cytotoxicity of daunorubicin on drug-resistant leukaemia cells with microparticle-mediated drug delivery system

References

• Alvarez-Erviti, L., et al., 2011. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature biotechnology, 29(4), 341–345.
   PubMed Web of Science ®Google Scholar
• Atai, N.A., et al., 2013. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. Journal of neuro-oncology, 115(3), 343–351.
   PubMed Web of Science ®Google Scholar
• Bebawy, M., et al., 2009. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia, 23(9), 1643–1649.
   PubMed Web of Science ®Google Scholar
• Christianson, H.C., et al., 2013. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proceedings of the national academy of sciences of the United States of America, 110(43), 17380–17385.
   PubMed Web of Science ®Google Scholar
• Costa Verdera, H., et al., 2017. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis. Journal of controlled release: official journal of the controlled release society, 266, 100–108.
   PubMed Web of Science ®Google Scholar
• Davizon, P., Munday, A., and López, J., 2010. Tissue factor, lipid rafts, and microparticles. Seminars in thrombosis and hemostasis, 36(08), 857–864.
   PubMed Web of Science ®Google Scholar
• Duan, Z.F., Brakora, K.A., and Seiden, M.V., 2004. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Molecular cancer therapeutics, 3, 833–838.
   PubMed Web of Science ®Google Scholar
• Gong, J., et al., 2013. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. European journal of pharmacology, 721(1-3), 116–125.
   PubMed Web of Science ®Google Scholar
• Gong, Y.P., et al., 2000. Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. Leukemia research, 24(9), 769–774.
   PubMed Web of Science ®Google Scholar
• Gottesman, M.M., Fojo, T., and Bates, S.E., 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews cancer, 2(1), 48–58.
   PubMed Web of Science ®Google Scholar
• Gyorgy, B., et al., 2011. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cellular and molecular life sciences, 68, 2667–2688.
   PubMed Web of Science ®Google Scholar
• Jaiswal, R., et al., 2017. Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion. BMC cancer, 17(1), 104–115.
   PubMed Web of Science ®Google Scholar
• Jin, X., et al., 2017. Pre-instillation of tumor microparticles enhances intravesical chemotherapy of nonmuscle-invasive bladder cancer through a lysosomal pathway. Biomaterials, 113, 93–104.
   PubMed Web of Science ®Google Scholar
• Johnsen, K.B., et al., 2014. A comprehensive overview of exosomes as drug delivery vehicles – endogenous nanocarriers for targeted cancer therapy. Biochimica et biophysica acta, 1846, 75–87.
   PubMed Web of Science ®Google Scholar
• Koivusalo, M., et al., 2010. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. The journal of cell biology, 188(4), 547–563.
   PubMed Web of Science ®Google Scholar
• Lopes-Rodrigues, V., et al., 2016. Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells. Biochimica et biophysica acta, 1860(3), 618–627.
   PubMed Web of Science ®Google Scholar
• Ma, J., et al., 2016. Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles. Cell research, 26(6), 713–727.
   PubMed Web of Science ®Google Scholar
• Marthinet, E., et al., 2000. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter. Gene therapy, 7(14), 1224–1233.
   PubMed Web of Science ®Google Scholar
• Mause, S.F., and Weber, C., 2010. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circulation research, 107(9), 1047–1057.
   PubMed Web of Science ®Google Scholar
• Miller, K.D., et al., 2016. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians, 66(4), 271–289.
   PubMed Web of Science ®Google Scholar
• Qian, J., et al., 2014. Differential requirements of arrestin-3 and clathrin for ligand-dependent and -independent internalization of human G protein-coupled receptor 40. Cell signal, 26(11), 2412–2423.
   PubMed Web of Science ®Google Scholar
• Ratajczak, J., et al., 2006. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia, 20(9), 1487–1495.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Abreu, D., Bordoni, A., and Zucca, E., 2007. Epidemiology of hematological malignancies. Annals of oncology : official journal of the european society for medical oncology, 18(Suppl 1), i3–i8.
   PubMed Web of Science ®Google Scholar
• Saari, H., et al., 2015. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. Journal of controlled release, 220, 727–737.
   PubMed Web of Science ®Google Scholar
• Seca, H., et al., 2011. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib. Hematology (Amsterdam, Netherlands), 16(2), 100–108.
   PubMed Web of Science ®Google Scholar
• Seiden, M.V., et al., 2002. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecologic oncology, 86(3), 302–310.
   PubMed Web of Science ®Google Scholar
• Sharom, F.J., 2008. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 9, 105–127.
   PubMed Web of Science ®Google Scholar
• Shen, F., et al., 2007. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. Journal of pharmacology and experimental therapeutics, 324(1), 95–102.
   PubMed Web of Science ®Google Scholar
• Silva, A.K., et al., 2015. Combining magnetic nanoparticles with cell derived microvesicles for drug loading and targeting. Nanomedicine: nanotechnology, biology, and medicine, 11(3), 645–655.
   PubMed Web of Science ®Google Scholar
• Stavrovskaya, A.A., 2000. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry-Moscow, 65, 95–106.
   PubMed Web of Science ®Google Scholar
• Tang, K., et al., 2010. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis. Biochemical and biophysical research communications, 400(3), 432–436.
   PubMed Web of Science ®Google Scholar
• Tang, K., et al., 2012. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nature communications, 3, 1282.
   PubMed Web of Science ®Google Scholar
• Thery, C., Ostrowski, M., and Segura, E., 2009. Membrane vesicles as conveyors of immune responses. Nature reviews immunology, 9(8), 581–593.
   PubMed Web of Science ®Google Scholar
• Wang, C., et al., 2017. A stronger reversal effect of the combination of dasatinib and menadione on P-gp-mediated multidrug resistance in human leukemia K562/Adr cell line. RSC advances, 7(28), 17227–17235.
   Web of Science ®Google Scholar
• Yang, T., et al., 2015. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharmaceutical research, 32(6), 2003–2014.
   PubMed Web of Science ®Google Scholar
• Zhou, J., et al., 2006. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer research, 66(1), 445–452.
   PubMed Web of Science ®Google Scholar
• Zhu, Y., et al., 2016. The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia. Journal of biomedical research, 30, 525–528.
   PubMed Web of Science ®Google Scholar